Federal and State Policy
As the largest US healthcare payer, the federal government plays a dominant role in shaping the healthcare marketplace, while states take center stage when it comes to developing novel policy approaches. Our experts track, interpret, and model policies that affect insurance coverage, access, and consumer choice so you can see around the bend.
Avalere Analysis: Medicaid Non-Expansion States Experience Up to 10% Enrollment Growth Due to Woodwork Effect
Over 550K New Medicaid Enrollees Gained Coverage in Non-Expansion States in First Quarter.
Managing Access to Pseudoephedrine: Potential Impacts of a Prescription-Only Policy versus Real-Time Stop Sale Technology
This April, Avalere experts finalized a paper surrounding the policy issues of control, access and usage for products containing pseudophedrine (PSE).
CBO and JCT Revise Health Reform Enrollment and Cost Estimates, Scale Back Medicaid Enrollment for 2014 and Premium Increases for 2015
On April 14, the Congressional Budget Office (CBO) and the Joint Committee on Taxation (JCT) released updated estimates on health insurance coverage provided through the ACA.
Downward Pressure on Medicare Advantage Payment Continues in Final Rate Notice
On April 7, CMS finalized their Calendar Year (CY) 2015 capitation rates, methodological changes to rates and risk models, and other payment and program policies for Medicare Advantage (MA) and Part D plans.
Avalere Analysis: Ten States Driving New Medicaid Enrollment
700K to 1.3M Additional Medicaid Enrollees through March, If Current Trends Continue.
Congress Proposes Bill to Expand New Technology Add-On Payments for Antibiotics under Medicare
In the July/August 2013 RPM Report, I co-wrote an article with Avalere's Scott Gottlieb and Lauren Barnes discussing the potential to use the new technology add-on payments (NTAPs), a novel pathway created by Congress in 2001, as a foundation for new policies that support innovation and address public health goals.
Congress Passes Drug Quality and Security Act; Includes Both Compounding and Track & Trace Provisions
On Nov. 18, the Senate passed the Drug Quality and Security Act, roughly two months after it passed the House in September, seeking to clarify laws related to human drug compounding and to strengthen the prescription drug supply chain by creating a national system.
Infographic: A View of Broad-Based Efforts to Engage Patients
As regulators struggle to find answers to differing needs across the healthcare sector, patients are becoming a more integral part in shaping policy.